...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of tissue engineering and regenerative medicine >The effect of serum on the proliferation of bone marrow-derived mesenchymal stem cells from aged donors and donors with or without chronic heart failure
【24h】

The effect of serum on the proliferation of bone marrow-derived mesenchymal stem cells from aged donors and donors with or without chronic heart failure

机译：血清对老年供体和供体的骨髓衍生间充质干细胞增殖的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Many clinical studies of regenerative medicine using bone marrow-derived mesenchymal stem cells (MSCs) have been conducted globally. We initiated clinical studies using MSCs in 2001 and have now treated over 100 cases with patients aged 0-92years. In a few cases involving patients with chronic heart failure (CHF), we observed that MSCs proliferated poorly. This contrasts with cell therapy studies wherein MSCs of patients with CHF were used for treatment. The effects of serum on the proliferation of MSCs from donors with normal heart function and with CHF have not been reported. Moreover, whether cell therapy is effective for elderly patients remains uncertain. Therefore, characterization of MSCs from aged donors and/or donors with CHF is urgently required. We retrospectively analysed the population doubling times (PDTs) of MSCs between the first and second passages. Although we had data for many samples of well-expanded MSCs from aged donors, a positive correlation was observed between donor age and PDT. A trend towards reduced variance in PDTs was observed in MSCs supplemented with fetal bovine serum (FBS) compared with those supplemented with autologous serum. When autologous serum was used, the average PDT of MSCs from donors with CHF was significantly longer than that of MSCs from donors without CHF. In contrast, when FBS was used, similar PDTs were observed in MSCs from donors with and without CHF. Thus, FBS promotes MSC expansion even from donors with CHF and MSC-based regenerative medicine might be feasible even for elderly patients. Copyright (C) 2016 John Wiley & Sons, Ltd.
机译：利用骨髓间充质干细胞（MSCs）进行的许多再生医学临床研究已经在全球范围内展开。我们在2001年开始使用骨髓间充质干细胞进行临床研究，目前已经治疗了100多例年龄在0-92岁的患者。在少数涉及慢性心力衰竭（CHF）患者的病例中，我们观察到MSC增殖不良。这与细胞治疗研究形成对比，在细胞治疗研究中，CHF患者的MSC被用于治疗。血清对心功能正常和CHF供体间充质干细胞增殖的影响尚未见报道。此外，细胞疗法对老年患者是否有效仍不确定。因此，迫切需要对老年供体和/或CHF供体的MSC进行鉴定。我们回顾性分析了第一代和第二代间骨髓间充质干细胞的群体倍增时间（PDT）。虽然我们有来自老年供体的许多扩增良好的MSC样本的数据，但在供体年龄和PDT之间观察到正相关。与添加自体血清的骨髓间充质干细胞相比，添加胎牛血清（FBS）的骨髓间充质干细胞的PDT差异有减少的趋势。当使用自体血清时，CHF供体骨髓间充质干细胞的平均PDT显著长于非CHF供体骨髓间充质干细胞的平均PDT。相比之下，当使用FBS时，在患有和不患有CHF的供体骨髓间充质干细胞中观察到类似的PDT。因此，即使来自CHF供体，FBS也能促进MSC的扩张，即使对于老年患者，基于MSC的再生医学也可能是可行的。版权所有（C）2016约翰威利父子有限公司。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号